Time period | I: 1983-1987 | II: 1988-1992 | III: 1993-1997 | IV: 1998-2002 | V: 2003-2007 | |
---|---|---|---|---|---|---|
n = 143(%) | n = 98(%) | n = 69(%) | n = 108(%) | n = 85(%) | ||
Gender | M | 115(80.4) | 76(77.6) | 52(75.4) | 92(85.2) | 65(76.5) |
MCR | (84.0) | (83.2) | (83.0) | (79.0) | (80.4) | |
Age | median y | 59 | 60 | 59 | 60 | 65 |
MCR | 58 | 59 | 61 | 65 | 66 | |
Histology | AC/SCC | 23(16.1)/117(81.8) | 14(14.3)/81(82.7) | 12(17.4)/56(81.2) | 23(21.3)/81(75) | 23(27.1)/60(70.6) |
MCR | (16.5)/(83.5) | (22.9)/(77.1) | (27.6)/(72.4) | |||
Grading | G3+4 | 61(42.7) | 48(49) | 40(58) | 64(59.3) | 49(57.6) |
T | T3+4 | 76(53.2) | 61(62.2) | 55(79.7) | 90(83.4) | 65(76.6) |
N1 | 53(37.1) | 36(36.7) | 40(58) | 65(60.2) | 59(69.4) | |
M1 | 27(20.9) | 17(19.1) | 15(22.1) | 29(27.6) | 25(29.8) | |
UICC | I-IIB | 68(47.6) | 45(45.9) | 24(34.8) | 32(29.6) | 21(24.7) |
MCR | (34.4) | (37.0) 1988-2007 | ||||
III-IV | 61(42.7) | 43(43.9) | 43(62.3) | 74(68.5) | 63(74.1) | |
MCR | (51.1) | (63.1) 1988-2007 | ||||
unknown | 14(9.8) | 10(10.2) | 2(2.9) | 2(1.9) | 1(1.2) | |
Therapy | definitive | 94(65.7) | 66(67.3) | 49(71) | 77(71.3) | 67(78.8) |
RT/RCT | 55(58.5)/38(40.4) | 37(56.1)/29(43.9) | 13(26.5)/36(73.5) | 10(13)/67(87) | 11(16.4)/56(83.6) | |
adjuvant | 21(14.7) | 4(4.1) | 9(13.0) | 10(9.3) | 7(8.2) | |
RT/RCT | 14(66.7)/4(19) | 1(25)/3(75) | 3(33.3)/6(66.7) | 2(20)/8(80) | 0/7(100) | |
neoadjuvant | 20(14.0) | 24(24.5) | 10(14.5) | 19(17.6) | 10(11.8) | |
RT/RCT | 7(35)/12(60) | 4(16.7)/19(79.2) | 2(20)/8(80) | 3(15.8)/16(84.2) | 1(10)/8(80) | |
RT, M0-patients | 56(56.6) | 26(36.1) | 13(24.5) | 9(11.8) | 6(10.3) | |
RCT, M0-patients | 43(43.4) | 46(63.9) | 40(75.5) | 67(88.2) | 52(89.7) | |
Surgery, M0-patients | 33(32.7) | 22(30.6) | 16(30.2) | 25(33.8) | 16(27.1) | |
RT dose in Gy, M0-pat. | ≤54 | 45(47.4) | 36(50) | 23(43.4) | 38(51.4) | 20(33.9) |
> 54 - < 60 | 4(4.2) | 0 | 6(11.3) | 17(23) | 27(45.8) | |
60+ | 46(48.4) | 36(50) | 24(45.3) | 19(25.7) | 12(20.3) | |
2D/3D-planning | 142(99.3)/0 | 98(100)/0 | 65(94.2)/1(1.4) | 7(6.5)/99(91.7) | 2(2.4)/82(96.5) | |
Peri-therapy death | 19(13.3) | 11(11.2) | 9(13.0) | 15(13.9) | 8(9.5) | |
Therapy break up due to complications | 13(9.1) | 4(4.1) | 7(10.1) | 13(12.0) | 6(7.1) | |
Overall survival all/M0 | median | 18.9/20.7 | 20.6/26.1 | 22.6/27.3 | 20.7/24.3 | 20.3/29.7 |
1 y | (41.1)/(43.7) | (40.2)/(52.2) | (44.9)/(54.7) | (40.7)/(44.7) | (48.8)/(58.7) | |
3 y | (7.1)/(8.7) | (15.1)/(18.3) | (14.5)/(18.9) | (17.6)/(19.7) | (15.9)/(19.4) | |
5 y | (4.0)/(5.5) | (8.6)/(8.2) | (10.1)/(13.2) | (9.3)/(11.8) | (9.8)/(15.1) |